We found following mistakes in our paper published in Pharmaceuticals \[[@b1-pharmaceuticals-04-01293]\]:

In the published version "Paladini *et al*. reported that aliskiren 300 mg provided a sustained BP-lowering effect beyond the 24-h dosing interval, with a significantly smaller loss of BP-lowering effect in the 24-48 h period after dose than irbesartan 300 mg or ramipril 10 mg \[25\]". Paladini *et al*. should be Palatini *et al*., and the cited reference number should be \[10\], not \[25\]..

In the sentence, "Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors \[18--30\]" one more citation number was added \[5\], so the revised sentence is "Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors \[5,18--30\]".
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